[{"id":"1c48e572-289e-4bd6-8e9e-55f35357c771","acronym":"SCALOP-2","url":"https://clinicaltrials.gov/study/NCT02024009","created_at":"2025-02-25T14:34:28.767Z","updated_at":"2025-02-25T14:34:28.767Z","phase":"Phase 1/2","brief_title":"Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2","source_id_and_acronym":"NCT02024009 - SCALOP-2","lead_sponsor":"University of Oxford","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • albumin-bound paclitaxel • Viracept (nelfinavir)"],"overall_status":"Completed","enrollment":" Enrollment 159","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 06/23/2021","primary_completion_date":" 06/23/2021","study_txt":" Completion: 06/23/2021","study_completion_date":" 06/23/2021","last_update_posted":"2024-07-25"},{"id":"e0dcfabe-9736-4024-9d54-13cb06f97e30","acronym":"SAKK 65/08","url":"https://clinicaltrials.gov/study/NCT01164709","created_at":"2021-01-18T04:38:37.477Z","updated_at":"2024-07-02T16:36:59.561Z","phase":"Phase 1","brief_title":"Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer","source_id_and_acronym":"NCT01164709 - SAKK 65/08","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Viracept (nelfinavir)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 07/01/2012","primary_completion_date":" 07/01/2012","study_txt":" Completion: 11/01/2013","study_completion_date":" 11/01/2013","last_update_posted":"2019-05-15"},{"id":"2214b856-b2d7-49fd-b17c-ae1344695b73","acronym":"","url":"https://clinicaltrials.gov/study/NCT00436735","created_at":"2021-01-18T01:32:30.542Z","updated_at":"2024-07-02T16:37:17.257Z","phase":"Phase 1","brief_title":"Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors","source_id_and_acronym":"NCT00436735","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CYP3A4","pipe":"","alterations":" ","tags":["CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Viracept (nelfinavir) • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2006","start_date":" 09/01/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-06"}]